[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100551415":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":26,"centralContacts":30,"locations":40,"responsibleParty":80,"collaborators":34,"id":82,"slug":83,"hasResults":84,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":84,"sex":90,"minAge":91,"maxAge":34,"enrollmentInfo":92,"targetDuration":34,"studyType":95,"phases":96,"briefSummary":98,"conditions":99,"keywords":101,"overallStatus":42,"whyStopped":34,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":116},{"fullName":5,"class":6},"Institut Curie","OTHER",[8,13],{"label":9,"type":6,"description":10,"interventionNames":11},"Line N in step 1","Step 1: follow-up of line N (standard care) when the tumorogram is established. Intervention is the biopsy performed before start of treatment in line N. Standard of Care treatment",[12],"Procedure: Biopsy",{"label":14,"type":15,"description":16,"interventionNames":17},"Line N+1 in step 2","EXPERIMENTAL","Step 2: in case of informative tumorogram: follow-up of experimental line N+1. If tumorogram is informative on organoid issued from biospy, a specific standard of Care treatment will be recommanded.",[12],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"PROCEDURE","Biopsy","The recommandation done based on informative tumorogram is up to study investigator",[9,14],[25],"Line N+1 treatment recommandation",[27],{"name":28,"affiliation":5,"role":29},"Luc CABEL, MD","PRINCIPAL_INVESTIGATOR",[31,36],{"name":28,"role":32,"phone":33,"phoneExt":34,"email":35},"CONTACT","+33 1 56 24 55 00",null,"drci.promotion@curie.fr",{"name":37,"role":32,"phone":38,"phoneExt":34,"email":39},"Anne-Sophie Plissonnier","+33 1 47 11 23 78","anne-sophie.plissonnier@curie.fr",[41,57,68],{"facility":5,"status":42,"city":43,"state":34,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"RECRUITING","Paris","75005","France","FR",{"type":48,"coordinates":49},"Point",[50,51],2.3488,48.85341,{"lat":51,"lon":50},[54,55],{"name":28,"role":32,"phone":34,"phoneExt":34,"email":34},{"name":56,"role":29,"phone":34,"phoneExt":34,"email":34},"LUC CABEL, MD",{"facility":58,"status":59,"city":43,"state":34,"zip":60,"country":45,"countryCode":46,"cosmosGeoPoint":61,"geoPoint":63,"contacts":64},"Hôpital Saint-Louis - AP-HP Senopole","NOT_YET_RECRUITING","75010",{"type":48,"coordinates":62},[50,51],{"lat":51,"lon":50},[65,67],{"name":66,"role":32,"phone":34,"phoneExt":34,"email":34},"Delphine COCHEREAU, MD",{"name":66,"role":29,"phone":34,"phoneExt":34,"email":34},{"facility":5,"status":42,"city":69,"state":34,"zip":70,"country":45,"countryCode":46,"cosmosGeoPoint":71,"geoPoint":75,"contacts":76},"Saint-Cloud","92210",{"type":48,"coordinates":72},[73,74],2.20289,48.84598,{"lat":74,"lon":73},[77,79],{"name":78,"role":32,"phone":34,"phoneExt":34,"email":34},"Alexandre DE MOURA, MD",{"name":78,"role":29,"phone":34,"phoneExt":34,"email":34},{"type":81,"investigatorFullName":34,"investigatorTitle":34,"investigatorAffiliation":34,"oldNameTitle":34,"oldOrganization":34},"SPONSOR","100551415","efficacy-of-personalized-tumorogram-based-therapy-in-cancer-established-from-patient-derived-organoid-avatar-100551415",false,"NCT06459791","Efficacy of Personalized Tumorogram-based Therapy in Cancer Established From Patient-derived Organoid (AVATAR)","Efficacy of Personalized Tumorogram-based Therapy in Cancer Established From Patient-derived Biological Avatar: Proof-of-concept Study","AVATAR","Inclusion Criteria:\n\n1. Patient over 18 years of age\n2. Advanced breast cancer\n3. Triple-negative phenotype (HR-\u002FHER2-) or HR+\u002FHER2- after hormone resistance (progression after treatment with hormone therapy + CDK4\u002F6 inhibitor)\n4. Tumor measurable according to RECISTv1.1 criteria, accessible to biopsy\n5. Performans Status 0-1\n\nExclusion Criteria:\n\n1. More than 3 lines of chemotherapy in the advanced setting (excluding hormone therapy\u002FCDK4\u002F6 inhibitor)\n2. Progressive brain metastases\n3. Leptomeningeal metastasis","ALL","18 Years",{"count":93,"type":94},110,"ESTIMATED","INTERVENTIONAL",[97],"NA","A biopsy of a tumor lesion (breast or other localisation) will be performed for processing to establish avatars (patient-derived organoids -PDO). A personalized tumorogram for each patient will be provided, based on the results of the drug screening (= tumor predicted as sensitive, intermediate, resistant or non-evaluable for each drug tested). Patients with an informative tumorogram will receive one of the recommended treatments (line N+1) in the event of tumor progression, administered according to standard procedures and validated at medical meetings specific to each center, and their fate will be monitored.",[100],"Metastatic Breast Cancer",[102,103,104,105,106],"tumorogram","metastatic breast cancer","avatar","Organoid","PDO","2026-01-27",{"date":109,"type":110},"2026-01-29","ACTUAL",{"date":112,"type":110},"2024-12-06",{"date":114,"type":94},"2028-09-30",{"name":5,"class":6},3]